Journal article

Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor

FGM Verspoor, MJL Mastboom, G Hannink, RG Maki, A Wagner, E Bompas, J Desai, A Italiano, BM Seddon, WTA van der Graaf, J-Y Blay, M Brahmi, L Eberst, S Stacchiotti, O Mir, MAJ van de Sande, H Gelderblom, PA Cassier

Scientific Reports | NATURE PUBLISHING GROUP | Published : 2019

Abstract

Tenosynovial giant cell tumors (TGCT), are rare colony stimulating factor-1(CSF-1)-driven proliferative disorders affecting joints. Diffuse-type TGCT often causes significant morbidity due to local recurrences necessitating multiple surgeries. Imatinib mesylate (IM) blocks the CSF-1 receptor. This study investigated the long term effects of IM in TGCT. We conducted an international multi-institutional retrospective study to assess the activity of IM: data was collected anonymously from individual patients with locally advanced, recurrent or metastatic TGCT. Sixty-two patients from 12 institutions across Europe, Australia and the United States were identified. Four patients with metastatic TG..

View full abstract